DIA China has appointed biopharmaceutical executive Haijun (Lou) Dong, PhD, as its managing director.
DIA (Drug Information Association) China has appointed biopharmaceutical executive Haijun (Lou) Dong, PhD, as its managing director.
Dong previously held executive positions as CEO for Lilly China Research and Development Co., a subsidiary of Eli Lilly and Company, and was president and CEO of IMPACT Therapeutics, Inc. He has been employed by Roche in China and the U.S., and by other Chinese and international companies, working in R&D, sales and marketing, business development and executive management.
Dong is a full professor at Nanjing University of Technology, and was named a “Leading Talent in Creativity, Innovation and Entrepreneurship” by the Nanjing New & High Technology Industry Development Zone. He holds an MBA from the China Europe International Business School and a doctorate in chemistry from the University of Washington.
This appointment was prompted by the retirement of Jane Cai, PhD, from the role of DIA China regional director. Under her direction, DIA China was established in 2011 as a legal entity, DIA Beijing Healthcare Information Consulting Ltd. Also, participation of attendees and exhibitors in DIA China Annual Meeting participation doubled, as did membership numbers.
Read the full release here.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.